About Telix
Telix is a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals. Telix’s extensive pipeline for urologic oncology, neuro-oncology, musculoskeletal oncology and hematology is underpinned by a strong global supply, manufacturing and distribution network.
Telix has received global regulatory approvals from the U.S. Food and Drug Administration (FDA), the Australian Therapeutic Goods Administration (TGA), and Health Canada for its prostate cancer imaging agent and has more than 18 clinical trials underway worldwide (including partnered studies).